Upgrade to SI Premium - Free Trial

Clearmind Medicine (CMND)

6.05 +0.11 (1.85%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (12/15/25 *Est.)

Latest Headlines

Form 6-K Clearmind Medicine Inc. For: Oct 16 October 16, 2026 4:01 PM - SEC Filing Form 6-K Clearmind Medicine Inc. For: Oct 13 October 13, 2026 6:17 AM - SEC Filing Charging Robotics unveils wireless EV charging platform for autonomo October 12, 2026 7:56 AM - StreetInsider Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets October 12, 2026 7:55 AM - StreetInsider Form 6-K Clearmind Medicine Inc. For: Oct 08 October 8, 2026 7:56 AM - SEC Filing Clearmind patent application for dyskinesia treatment published in Japan October 8, 2026 7:34 AM - StreetInsider Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder October 8, 2026 7:32 AM - StreetInsider Form 6-K Clearmind Medicine Inc. For: Oct 07 October 7, 2026 8:41 AM - SEC Filing Clearmind submits psychedelic therapy recommendations to FDA October 7, 2026 8:41 AM - StreetInsider Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA October 7, 2026 8:40 AM - StreetInsider Form 6-K Clearmind Medicine Inc. For: Sep 30 September 30, 2026 4:30 PM - SEC Filing NeuroThera files 3 U.S. patents on LSD, ketamine, ibogaine combos September 23, 2026 8:35 AM - StreetInsider SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations September 23, 2026 8:35 AM - StreetInsider Form 6-K Clearmind Medicine Inc. For: Sep 23 September 23, 2026 8:00 AM - SEC Filing Clearmind files 3 U.S. patent applications on LSD, ketamine, ibogaine September 23, 2026 7:59 AM - StreetInsider Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations September 23, 2026 7:57 AM - StreetInsider Form 6-K Clearmind Medicine Inc. For: Sep 17 September 17, 2026 4:00 PM - SEC Filing Clearmind Medicine testifies at FDA psychedelic hearing in D.C. September 17, 2026 7:44 AM - StreetInsider Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C. September 17, 2026 7:42 AM - StreetInsider Form 6-K Clearmind Medicine Inc. For: Sep 14 September 14, 2026 6:09 AM - SEC Filing Clearmind enrolls first AUD patients in CMND-100 trial September 11, 2026 8:01 AM - StreetInsider Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial September 11, 2026 8:00 AM - StreetInsider Form 6-K Clearmind Medicine Inc. For: Jul 31 September 10, 2026 4:06 PM - SEC Filing Yale approves Clearmind Medicine patient recruitment for CMND-100 trial September 8, 2026 7:43 AM - StreetInsider Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results September 8, 2026 7:42 AM - StreetInsider Clearmind Medicine to acquire 51% of EV wireless charging firm September 4, 2026 7:32 AM - StreetInsider Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis September 4, 2026 7:32 AM - StreetInsider Clearmind starts Phase IIa trial of CMND-100 for alcohol disorder September 1, 2026 7:37 AM - StreetInsider Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled September 1, 2026 7:37 AM - StreetInsider Form 6-K Clearmind Medicine Inc. For: Aug 24 August 24, 2026 4:01 PM - SEC Filing SciSparc unit files U.S. patent for MDMA-PEA combination for PTSD August 24, 2026 8:51 AM - StreetInsider SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation August 24, 2026 8:51 AM - StreetInsider Clearmind files U.S. patent for MDMA-PEA combination to treat PTSD August 24, 2026 8:05 AM - StreetInsider Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation August 24, 2026 8:03 AM - StreetInsider Clearmind gets DSMB approval to test CMND-100 in AUD patients August 13, 2026 7:36 AM - StreetInsider Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint August 13, 2026 7:36 AM - StreetInsider Form SCHEDULE 13G/A Clearmind Medicine Inc. Filed by: Iroquois Capital Management, LLC August 12, 2026 10:46 AM - SEC Filing Form 6-K Clearmind Medicine Inc. For: Aug 11 August 11, 2026 4:01 PM - SEC Filing Form 6-K Clearmind Medicine Inc. For: Aug 06 August 6, 2026 4:00 PM - SEC Filing Clearmind gets clearance to advance AUD drug trial to patient cohorts August 6, 2026 8:00 AM - StreetInsider Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study August 6, 2026 8:00 AM - StreetInsider Form 6-K Clearmind Medicine Inc. For: Aug 03 August 3, 2026 8:12 AM - SEC Filing Clearmind Medicine eyes 51% stake in EV wireless charging firm August 3, 2026 8:02 AM - StreetInsider Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company August 3, 2026 8:02 AM - StreetInsider Form 6-K Clearmind Medicine Inc. For: Jul 30 July 30, 2026 4:01 PM - SEC Filing Clearmind reports no serious adverse events in CMND-100 dose trial July 30, 2026 8:30 AM - StreetInsider Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part A of its FDA-Regulated Clinical Trial July 30, 2026 8:30 AM - StreetInsider Clearmind completes Part A of Phase I/II trial for alcohol disorder drug July 28, 2026 7:47 AM - StreetInsider Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial July 28, 2026 7:47 AM - StreetInsider Full Article List